Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by Forestviewon Aug 06, 2021 4:04pm
195 Views
Post# 33664733

RE:RE:October RSUs

RE:RE:October RSUsHey MikeStock, here is the wording:

3. To consider and if thought appropriate, pass, with or without violation, an ordinary resolution of disinterested shareholders approving amendments to the Corporation's stock option plan, as described in the accompanying MIC

4. To consider and, if thought appropriate, pass with or without variation, an ordinary resolution or disinterested shareholders approving amendments to the Corporation's restricted share unit plan, as described in the accompanying Manangement Information Circular

I'm not the sharpest knife in the drawer, so I'd love some insight on what exactly this means.  Upon reflection, this seems that they are getting some Stock Options and RSUs regardless, it's just whether they're getting what they're currently on, or if it'll be an "enhanced" plan that's listed in the MIC.

Regardless.  I said no to both.  


MikeStock wrote: I don't have the voting docs in front of me, but I don't believe that is an actual voting decision. When I'm back home in a few days I can post the language related to the stock plan unless someone else has it handy. 

Forestview wrote: So, now that the stock has tanked, what's the implication for the RSUs in October?  

Also, now is a good reminder to vote ahead of the AGM against a new issue of RSUs for the management team.  If you're ticked off, like most of us here are, vote.  Let the management team and board know.  




<< Previous
Bullboard Posts
Next >>